Excelsior Biopharma Inc. (TPEX:6496)
Taiwan
· Delayed Price · Currency is TWD 26.20
-0.85 (-3.14%)
At close: Mar 9, 2026
Excelsior Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 | Upgrade
|
| Depreciation & Amortization | 71.68 | 70.96 | 46.22 | 26.06 | 28.65 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.65 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | 0.21 | Upgrade
|
| Loss (Gain) on Equity Investments | -2.18 | -0.25 | - | - | - | Upgrade
|
| Stock-Based Compensation | 0.28 | 0.33 | 0.26 | 0.04 | - | Upgrade
|
| Provision & Write-off of Bad Debts | -2.56 | 2.25 | 0.98 | -3.67 | 4.47 | Upgrade
|
| Other Operating Activities | -1.8 | 2.81 | 6.75 | 0.78 | 5.53 | Upgrade
|
| Change in Accounts Receivable | -45.81 | -30.53 | -27.17 | 82.26 | -35.87 | Upgrade
|
| Change in Inventory | 17.75 | -85.65 | -28.7 | 16.02 | 71.88 | Upgrade
|
| Change in Accounts Payable | -38.78 | 42.43 | -16.92 | -49.79 | -18.52 | Upgrade
|
| Change in Other Net Operating Assets | 45.22 | -3.44 | -25.15 | -32.46 | 15.13 | Upgrade
|
| Operating Cash Flow | -138.72 | -99.8 | -134.75 | 5.49 | 55.82 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | -90.17% | -89.28% | Upgrade
|
| Capital Expenditures | -36.95 | -257.15 | -35.66 | -7.78 | -2.88 | Upgrade
|
| Sale of Property, Plant & Equipment | 2.25 | - | - | - | - | Upgrade
|
| Investment in Securities | 11.45 | -55.5 | 199.74 | -200 | -6.01 | Upgrade
|
| Other Investing Activities | -1.15 | 5.62 | -17.47 | 8.54 | -1.8 | Upgrade
|
| Investing Cash Flow | -24.4 | -307.03 | 146.62 | -199.24 | -10.68 | Upgrade
|
| Short-Term Debt Issued | 159.61 | 0.01 | 0.01 | - | - | Upgrade
|
| Long-Term Debt Issued | - | 110 | - | - | - | Upgrade
|
| Total Debt Issued | 159.61 | 110.01 | 0.01 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -0.01 | -0.01 | - | - | Upgrade
|
| Long-Term Debt Repaid | -51.97 | -53.98 | -317.23 | -13.73 | -12.64 | Upgrade
|
| Total Debt Repaid | -51.97 | -53.99 | -317.24 | -13.73 | -12.64 | Upgrade
|
| Net Debt Issued (Repaid) | 107.64 | 56.02 | -317.23 | -13.73 | -12.64 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -23.74 | Upgrade
|
| Common Dividends Paid | - | - | - | - | -46.67 | Upgrade
|
| Other Financing Activities | 0.74 | 0.98 | - | - | - | Upgrade
|
| Financing Cash Flow | 108.38 | 56.99 | -317.23 | -13.73 | -83.04 | Upgrade
|
| Net Cash Flow | -54.74 | -349.84 | -305.36 | -207.49 | -37.9 | Upgrade
|
| Free Cash Flow | -175.67 | -356.95 | -170.41 | -2.3 | 52.95 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -89.60% | Upgrade
|
| Free Cash Flow Margin | -19.56% | -41.41% | -22.09% | -0.34% | 3.96% | Upgrade
|
| Free Cash Flow Per Share | -3.81 | -7.74 | -3.71 | -0.05 | 1.14 | Upgrade
|
| Cash Interest Paid | 7.65 | 7.96 | 1.36 | 0.88 | 1.12 | Upgrade
|
| Cash Income Tax Paid | 12.4 | 8.36 | 8.38 | 8.28 | 3.46 | Upgrade
|
| Levered Free Cash Flow | -104.35 | -311.04 | -139.51 | 4.43 | 59.32 | Upgrade
|
| Unlevered Free Cash Flow | -99.49 | -306.02 | -135.53 | 7.15 | 62.16 | Upgrade
|
| Change in Working Capital | -21.62 | -77.19 | -97.95 | 16.03 | 32.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.